Clinical Development of PARP Inhibitors in Treating Metastatic Castration-Resistant Prostate Cancer

The approval of upfront abiraterone for castration-sensitive prostate cancer and the approval of enzalutamide and apalutamide for non-metastatic castration-resistant prostate cancer have led to early utilization of potent androgen receptor (AR) signaling inhibitors in treating advanced prostate canc...

Descripción completa

Detalles Bibliográficos
Autores principales: Adashek, Jacob J., Jain, Rohit K., Zhang, Jingsong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6721701/
https://www.ncbi.nlm.nih.gov/pubmed/31404966
http://dx.doi.org/10.3390/cells8080860

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6721701/
https://www.ncbi.nlm.nih.gov/pubmed/31404966
http://dx.doi.org/10.3390/cells8080860

Ejemplares similares